SEC Filing Summary: Primedex Health Systems, Inc. (10-Q)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended January 31, 1997, for Primedex Health Systems, Inc. (PHS) and its affiliates. The company operates primarily through its subsidiaries, including Radnet, Future Diagnostics, Inc. (FDI), and Diagnostic Imaging Services, Inc. (DIS). The financial statements are unaudited. Note: While the request metadata mentions "Radnet, Inc.," the filing registrant is Primedex Health Systems, Inc., which controls Radnet.
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 |
|---|---|---|
| Net Revenue | $17,637,122 | $13,839,451 |
| Operating Loss | $(5,194,370) | $984,294 (Income) |
| Net Loss | $(7,808,880) | $(163,944) |
| Loss Per Share | $(0.20) | $(0.01) |
| Cash and Equivalents (End) | $176,015 | $1,333,286 |
| Total Debt (Current + Long-Term) | $113,497,689 | N/A (Not explicitly summed) |
| Working Capital Deficit | $(24,765,098) | N/A |
Liquidity: The company reported a net working capital deficit of approximately $24.8 million. Cash increased slightly by $24,145 during the quarter, driven by operating cash flow of $1.46 million, offset by investing and financing outflows.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased by approximately 27% year-over-year, primarily driven by the inclusion of the new DIS subsidiary.
- Profitability Decline: The company swung from an operating income of $984,294 in Q1 1996 to an operating loss of $5.19 million in Q1 1997.
- Impairment Charges: A significant non-cash impairment loss of $4,953,783 was recorded in Q1 1997 related to the planned closure of the DIS "Parkside" facility. This included write-offs of property, equipment, and goodwill.
- Interest Expense: Interest expense rose to $2.66 million from $1.65 million, attributed to increased debt levels and lines of credit associated with the DIS acquisition.
Outlook, Risks, and Contingencies
- Subsequent Asset Sales: Following the quarter-end, DIS sold its ultrasound division and four hospital-based MRI facilities for approximately $25 million in total proceeds. The company estimates a gain of $4.9 million on these sales, with $7.6 million of cash proceeds used to pay down existing debt.
- Debt Obligations: The company relies on three lines of credit totaling approximately $14.65 million outstanding as of January 31, 1997. Future debt and lease payments over the next five years are projected to be substantial, totaling over $100 million.
- Litigation:
- Securities Litigation: A preliminary settlement of $240,000 was reached in a class action suit, pending final court approval.
- Contract Dispute: A complaint was filed by Dr. Gerald E. Dalrymple alleging unpaid fees and seeking damages exceeding $25,000, plus a potential $1 million claim related to warrant conversion. The company intends to vigorously defend against these allegations.
- Restructuring: Estimated closing costs for discontinued operations and closed centers remain on the books, with approximately $737,000 accrued for legal and settlement costs.
Investor Verification Checklist
- Debt Covenants: Verify the status of the three lines of credit, particularly the DIS line extended on a month-to-month basis, and ensure compliance with collateral requirements.
- Subsequent Sales Closing: Confirm the final closing of the $25 million asset sale (ultrasound and MRI facilities) and the actual cash proceeds received versus the estimated $4.9 million gain.
- Litigation Exposure: Monitor the final court approval of the $240,000 securities settlement and the outcome of the Dalrymple lawsuit regarding the $1 million warrant claim.
- Working Capital: Assess the sustainability of operations given the $24.8 million working capital deficit and the heavy reliance on short-term borrowings.
- Impairment Accuracy: Review the valuation of remaining assets at the Parkside facility and other centers to ensure no further write-downs are imminent.